{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T15:15:26Z","timestamp":1784128526565,"version":"3.55.0"},"reference-count":64,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,6,6]],"date-time":"2020-06-06T00:00:00Z","timestamp":1591401600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,6,6]],"date-time":"2020-06-06T00:00:00Z","timestamp":1591401600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"funder":[{"name":"Science and technology general project of Guangzhuo, China.","award":["201804010028"],"award-info":[{"award-number":["201804010028"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Rheumatol"],"published-print":{"date-parts":[[2021,1]]},"DOI":"10.1007\/s10067-020-05207-z","type":"journal-article","created":{"date-parts":[[2020,6,6]],"date-time":"2020-06-06T09:03:16Z","timestamp":1591434196000},"page":"25-32","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":18,"title":["Molecular mechanisms and clinical studies of iguratimod for the treatment of ankylosing spondylitis"],"prefix":"10.1007","volume":"40","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2728-5099","authenticated-orcid":false,"given":"Suling","family":"Liu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6053-5571","authenticated-orcid":false,"given":"Yang","family":"Cui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0331-0197","authenticated-orcid":false,"given":"Xiao","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,6,6]]},"reference":[{"key":"5207_CR1","doi-asserted-by":"crossref","first-page":"109704","DOI":"10.1016\/j.biopha.2019.109704","volume":"122","author":"H Jiang","year":"2020","unstructured":"Jiang H, Gao H, Wang Q, Wang M, Wu B (2020) Molecular mechanisms and clinical application of Iguratimod: a review. Biomed Pharmacother 122:109704","journal-title":"Biomed Pharmacother"},{"issue":"4","key":"5207_CR2","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1254\/jjp.67.305","volume":"67","author":"K Tanaka","year":"1995","unstructured":"Tanaka K, Kawasaki H, Kurata K et al (1995) T-614, a novel antirheumatic drug, inhibits both the activity and induction of cyclooxygenase-2 (COX-2) in cultured fibroblasts. Jpn J Pharmacol 67(4):305\u2013314","journal-title":"Jpn J Pharmacol"},{"issue":"4","key":"5207_CR3","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1007\/PL00000291","volume":"51","author":"Y Aikawa","year":"2002","unstructured":"Aikawa Y, Yamamoto M, Yamamoto T et al (2002) An anti-rheumatic agent T-614 inhibits NF-kappaB activation in LPS- and TNF-alpha-stimulated THP-1 cells without interfering with IkappaBalpha degradation. Inflamm Res 51(4):188\u2013194","journal-title":"Inflamm Res"},{"issue":"12","key":"5207_CR4","first-page":"2591","volume":"28","author":"M Kohno","year":"2001","unstructured":"Kohno M, Aikawa Y, Tsubouchi Y et al (2001) Inhibitory effect of T-614 on tumor necrosis factor-alpha induced cytokine production and nuclear factor-kappaB activation in cultured human synovial cells. J Rheumatol 28(12):2591\u20132596","journal-title":"J Rheumatol"},{"issue":"1","key":"5207_CR5","doi-asserted-by":"crossref","first-page":"1933","DOI":"10.1038\/s41598-018-20390-5","volume":"8","author":"G Li","year":"2018","unstructured":"Li G, Yamasaki R, Fang M et al (2018) Novel disease-modifying anti-rheumatic drug iguratimod suppresses chronic experimental autoimmune encephalomyelitis by down-regulating activation of macrophages\/microglia through an NF-\u03baB pathway. Sci Rep 8(1):1933","journal-title":"Sci Rep"},{"key":"5207_CR6","first-page":"214683","volume":"2015","author":"Y Wei","year":"2015","unstructured":"Wei Y, Sun X, Hua M et al (2015) Inhibitory effect of a novel antirheumatic drug T-614 on the IL-6-induced RANKL\/OPG, IL-17, and MMP-3 expression in synovial fibroblasts from rheumatoid arthritis patients. Biomed Res Int 2015:214683","journal-title":"Biomed Res Int"},{"issue":"10","key":"5207_CR7","doi-asserted-by":"crossref","first-page":"4969","DOI":"10.4049\/jimmunol.1300832","volume":"191","author":"Q Luo","year":"2013","unstructured":"Luo Q, Sun Y, Liu W, Qian C, Jin B, Tao F, Gu Y, Wu X, Shen Y, Xu Q (2013) A novel disease-modifying antirheumatic drug, iguratimod, ameliorates murine arthritis by blocking IL-17 signaling, distinct from methotrexate and leflunomide. J Immunol 191(10):4969\u20134978","journal-title":"J Immunol"},{"issue":"51","key":"5207_CR8","doi-asserted-by":"crossref","first-page":"26502","DOI":"10.1074\/jbc.M116.743328","volume":"291","author":"J Bloom","year":"2016","unstructured":"Bloom J, Metz C, Nalawade S et al (2016) Identification of iguratimod as an inhibitor of macrophage migration inhibitory factor (MIF) with steroid-sparing potential. J Biol Chem 291(51):26502\u201326514","journal-title":"J Biol Chem"},{"key":"5207_CR9","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1016\/j.intimp.2016.03.038","volume":"35","author":"K Gan","year":"2016","unstructured":"Gan K, Yang L, Xu L et al (2016) Iguratimod (T-614) suppresses RANKL-induced osteoclast differentiation and migration in RAW264.7 cells via NF-\u03baB and MAPK pathways. Int Immunopharmacol 35:294\u2013300","journal-title":"Int Immunopharmacol"},{"issue":"5","key":"5207_CR10","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1016\/S0006-291X(02)02754-7","volume":"299","author":"K Kuriyama","year":"2002","unstructured":"Kuriyama K, Higuchi C, Tanaka K et al (2002) A novel anti-rheumatic drug, T-614, stimulates osteoblastic differentiation in vitro and bone morphogenetic protein-2-induced bone formation in vivo. Biochem Biophys Res Commun 299(5):903\u2013909","journal-title":"Biochem Biophys Res Commun"},{"issue":"10089","key":"5207_CR11","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/S0140-6736(16)31591-4","volume":"390","author":"J Sieper","year":"2017","unstructured":"Sieper J, Poddubnyy D (2017) Axial spondyloarthritis. Lancet 390(10089):73\u201384","journal-title":"Lancet"},{"issue":"9570","key":"5207_CR12","doi-asserted-by":"crossref","first-page":"1379","DOI":"10.1016\/S0140-6736(07)60635-7","volume":"369","author":"J Braun","year":"2007","unstructured":"Braun J, Sieper J (2007) Ankylosing spondylitis. Lancet 369(9570):1379\u20131390","journal-title":"Lancet"},{"issue":"6","key":"5207_CR13","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1038\/nrrheum.2017.56","volume":"13","author":"V Ranganathan","year":"2017","unstructured":"Ranganathan V, Gracey E, Brown MA, Inman RD, Haroon N (2017) Pathogenesis of ankylosing spondylitis - recent advances and future directions. Nat Rev Rheumatol 13(6):359\u2013367","journal-title":"Nat Rev Rheumatol"},{"issue":"10","key":"5207_CR14","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1007\/s11926-019-0856-3","volume":"21","author":"SJ Pedersen","year":"2019","unstructured":"Pedersen SJ, Maksymowych WP (2019) The pathogenesis of ankylosing spondylitis: an update. Curr Rheumatol Rep 21(10):58","journal-title":"Curr Rheumatol Rep"},{"issue":"12","key":"5207_CR15","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1038\/nrrheum.2017.188","volume":"13","author":"G Schett","year":"2017","unstructured":"Schett G, Lories RJ, D\u2019Agostino MA et al (2017) Enthesitis: from pathophysiology to treatment. Nat Rev Rheumatol 13(12):731\u2013741","journal-title":"Nat Rev Rheumatol"},{"issue":"9","key":"5207_CR16","doi-asserted-by":"crossref","first-page":"1796","DOI":"10.1002\/art.40175","volume":"69","author":"V Ranganathan","year":"2017","unstructured":"Ranganathan V, Ciccia F, Zeng F et al (2017) Macrophage migration inhibitory factor induces inflammation and predicts spinal progression in ankylosing spondylitis. Arthritis Rheum 69(9):1796\u20131806","journal-title":"Arthritis Rheum"},{"issue":"1","key":"5207_CR17","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1111\/j.1365-2567.2008.02879.x","volume":"126","author":"I Stojanovi\u0107","year":"2009","unstructured":"Stojanovi\u0107 I, Cvjeti\u0107anin T, Lazaroski S, Sto\u0161i\u0107-Gruji\u010di\u0107 S, Miljkovi\u0107 D (2009) Macrophage migration inhibitory factor stimulates interleukin-17 expression and production in lymph node cells. Immunology 126(1):74\u201383","journal-title":"Immunology"},{"issue":"5","key":"5207_CR18","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1038\/nrrheum.2016.42","volume":"12","author":"J Sieper","year":"2016","unstructured":"Sieper J, Poddubnyy D (2016) New evidence on the management of spondyloarthritis. Nat Rev Rheumatol 12(5):282\u2013295","journal-title":"Nat Rev Rheumatol"},{"issue":"9894","key":"5207_CR19","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1016\/S0140-6736(13)60900-9","volume":"382","author":"N Bhala","year":"2013","unstructured":"Bhala N, Emberson J, Merhi A et al (2013) Vascular and upper gastrointestinal effects of non-steroidal anti-inflammatory drugs: meta-analyses of individual participant data from randomised trials. Lancet 382(9894):769\u2013779","journal-title":"Lancet"},{"issue":"6","key":"5207_CR20","doi-asserted-by":"crossref","first-page":"978","DOI":"10.1136\/annrheumdis-2016-210770","volume":"76","author":"D van der Heijde","year":"2017","unstructured":"van der Heijde D, Ramiro S, Landewe R et al (2017) 2016 update of the ASAS-EULAR management recommendations for axial spondyloarthritis. Ann Rheum Dis 76(6):978\u2013991","journal-title":"Ann Rheum Dis"},{"issue":"6","key":"5207_CR21","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.1136\/annrheumdis-2014-205322","volume":"74","author":"J Callhoff","year":"2015","unstructured":"Callhoff J, Sieper J, Wei\u00df A, Zink A, Listing J (2015) Efficacy of TNF\u03b1 blockers in patients with ankylosing spondylitis and non-radiographic axial spondyloarthritis: a meta-analysis. Ann Rheum Dis 74(6):1241\u20131248","journal-title":"Ann Rheum Dis"},{"issue":"2","key":"5207_CR22","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1136\/ard.2004.032565","volume":"65","author":"A Boonen","year":"2006","unstructured":"Boonen A, van der Heijde D, Severens JL et al (2006) Markov model into the cost-utility over five years of etanercept and infliximab compared with usual care in patients with active ankylosing spondylitis. Ann Rheum Dis 65(2):201\u2013208","journal-title":"Ann Rheum Dis"},{"issue":"26","key":"5207_CR23","doi-asserted-by":"crossref","first-page":"2534","DOI":"10.1056\/NEJMoa1505066","volume":"373","author":"D Baeten","year":"2015","unstructured":"Baeten D, Sieper J, Braun J et al (2015) Secukinumab, an interleukin-17A inhibitor, in ankylosing spondylitis. N Engl J Med 373(26):2534\u20132548","journal-title":"N Engl J Med"},{"issue":"7","key":"5207_CR24","first-page":"935","volume":"42","author":"K Tanaka","year":"1992","unstructured":"Tanaka K, Shimotori T, Makino S et al (1992) Pharmacological studies of the new antiinflammatory agent 3-formylamino-7-methylsulfonylamino-6-phenoxy-4H-1-benzopyran-4-o ne. 1st communication: antiinflammatory, analgesic and other related properties. Arzneimittel-Forschung 42(7):935\u2013944","journal-title":"Arzneimittel-Forschung"},{"issue":"7","key":"5207_CR25","first-page":"945","volume":"42","author":"K Tanaka","year":"1992","unstructured":"Tanaka K, Makino S, Shimotori T et al (1992) Pharmacological studies of the new antiinflammatory agent 3-formylamino-7-methylsulfonylamino-6-phenoxy-4\u2032-1-benzopyran-4-o ne. 2nd communication: effect on the arachidonic acid cascades. Arzneimittel-Forschung 42(7):945\u2013950","journal-title":"Arzneimittel-Forschung"},{"issue":"8","key":"5207_CR26","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1038\/ng.873","volume":"43","author":"DM Evans","year":"2011","unstructured":"Evans DM, Spencer CC, Pointon JJ et al (2011) Interaction between ERAP1 and HLA-B27 in ankylosing spondylitis implicates peptide handling in the mechanism for HLA-B27 in disease susceptibility. Nat Genet 43(8):761\u2013767","journal-title":"Nat Genet"},{"issue":"1","key":"5207_CR27","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1002\/1529-0131(199801)41:1<122::AID-ART15>3.0.CO;2-8","volume":"41","author":"I Siegle","year":"1998","unstructured":"Siegle I, Klein T, Backman JT et al (1998) Expression of cyclooxygenase 1 and cyclooxygenase 2 in human synovial tissue: differential elevation of cyclooxygenase 2 in inflammatory joint diseases. Arthritis Rheum 41(1):122\u2013129","journal-title":"Arthritis Rheum"},{"issue":"3","key":"5207_CR28","doi-asserted-by":"crossref","first-page":"1364","DOI":"10.4049\/jimmunol.1300274","volume":"191","author":"SM Paulissen","year":"2013","unstructured":"Paulissen SM, van Hamburg JP, Davelaar N et al (2013) Synovial fibroblasts directly induce Th17 pathogenicity via the cyclooxygenase\/prostaglandin E2 pathway, independent of IL-23. J Immunol 191(3):1364\u20131372","journal-title":"J Immunol"},{"issue":"7","key":"5207_CR29","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1007\/s00011-018-1153-8","volume":"67","author":"JS Samuels","year":"2018","unstructured":"Samuels JS, Holland L, Lopez M et al (2018) Prostaglandin E2 and IL-23 interconnects STAT3 and RoR\u03b3 pathways to initiate Th17 CD4 T-cell development during rheumatoid arthritis. Inflamm Res 67(7):589\u2013596","journal-title":"Inflamm Res"},{"issue":"6","key":"5207_CR30","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1038\/nri3834","volume":"15","author":"D Brenner","year":"2015","unstructured":"Brenner D, Blaser H, Mak TW (2015) Regulation of tumour necrosis factor signalling: live or let die. Nat Rev Immunol 15(6):362\u2013374","journal-title":"Nat Rev Immunol"},{"issue":"4","key":"5207_CR31","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1089\/jir.1998.18.219","volume":"18","author":"MD Crew","year":"1998","unstructured":"Crew MD, Effros RB, Walford RL et al (1998) Transgenic mice expressing a truncated Peromyscus leucopus TNF-alpha gene manifest an arthritis resembling ankylosing spondylitis. J Interf Cytokine Res 18(4):219\u2013225","journal-title":"J Interf Cytokine Res"},{"issue":"3","key":"5207_CR32","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1002\/art.20194","volume":"50","author":"K Redlich","year":"2004","unstructured":"Redlich K, G\u00f6rtz B, Hayer S et al (2004) Overexpression of tumor necrosis factor causes bilateral sacroiliitis. Arthritis Rheum 50(3):1001\u20131005","journal-title":"Arthritis Rheum"},{"issue":"4","key":"5207_CR33","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1002\/art.1780380407","volume":"38","author":"J Braun","year":"1995","unstructured":"Braun J, Bollow M, Neure L et al (1995) Use of immunohistologic and in situ hybridization techniques in the examination of sacroiliac joint biopsy specimens from patients with ankylosing spondylitis. Arthritis Rheum 38(4):499\u2013505","journal-title":"Arthritis Rheum"},{"issue":"2","key":"5207_CR34","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/j.immuni.2011.02.012","volume":"34","author":"Y Iwakura","year":"2011","unstructured":"Iwakura Y, Ishigame H, Saijo S et al (2011) Functional specialization of interleukin-17 family members. Immunity 34(2):149\u2013162","journal-title":"Immunity"},{"issue":"9","key":"5207_CR35","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1056\/NEJMra0707449","volume":"361","author":"P Miossec","year":"2009","unstructured":"Miossec P, Korn T, Kuchroo VK (2009) Interleukin-17 and type 17 helper T cells. N Engl J Med 361(9):888\u2013898","journal-title":"N Engl J Med"},{"key":"5207_CR36","doi-asserted-by":"crossref","first-page":"356040","DOI":"10.1155\/2015\/356040","volume":"2015","author":"Y Xu","year":"2015","unstructured":"Xu Y, Zhu Q, Song J et al (2015) Regulatory effect of iguratimod on the balance of Th subsets and inhibition of inflammatory cytokines in patients with rheumatoid arthritis. Mediat Inflamm 2015:356040\u2013356040","journal-title":"Mediat Inflamm"},{"issue":"7","key":"5207_CR37","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1038\/ng.2667","volume":"45","author":"A Cortes","year":"2013","unstructured":"International Genetics of Ankylosing Spondylitis C, Cortes A, Hadler J et al (2013) Identification of multiple risk variants for ankylosing spondylitis through high-density genotyping of immune-related loci. Nat Genet 45(7):730\u2013738","journal-title":"Nat Genet"},{"issue":"1","key":"5207_CR38","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1002\/art.33321","volume":"64","author":"S Glatigny","year":"2012","unstructured":"Glatigny S, Fert I, Blaton MA et al (2012) Proinflammatory Th17 cells are expanded and induced by dendritic cells in spondylarthritis-prone HLA-B27-transgenic rats. Arthritis Rheum 64(1):110\u2013120","journal-title":"Arthritis Rheum"},{"issue":"7","key":"5207_CR39","doi-asserted-by":"crossref","first-page":"1755","DOI":"10.1002\/art.38638","volume":"66","author":"H Benham","year":"2014","unstructured":"Benham H, Rehaume LM, Hasnain SZ, Velasco J, Baillet AC, Ruutu M, Kikly K, Wang R, Tseng HW, Thomas GP, Brown MA, Strutton G, McGuckin MA, Thomas R (2014) Interleukin-23 mediates the intestinal response to microbial \u03b2-1,3-glucan and the development of spondyloarthritis pathology in SKG mice. Arthritis Rheum 66(7):1755\u20131767","journal-title":"Arthritis Rheum"},{"issue":"2","key":"5207_CR40","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1007\/s10067-010-1647-4","volume":"30","author":"Y Mei","year":"2011","unstructured":"Mei Y, Pan F, Gao J et al (2011) Increased serum IL-17 and IL-23 in the patient with ankylosing spondylitis. Clin Rheumatol 30(2):269\u2013273","journal-title":"Clin Rheumatol"},{"issue":"3","key":"5207_CR41","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1016\/j.jbspin.2006.11.005","volume":"74","author":"D Wendling","year":"2007","unstructured":"Wendling D, Cedoz J-P, Racadot E, Dumoulin G (2007) Serum IL-17, BMP-7, and bone turnover markers in patients with ankylosing spondylitis. Joint Bone Spine 74(3):304\u2013305","journal-title":"Joint Bone Spine"},{"issue":"3","key":"5207_CR42","doi-asserted-by":"crossref","first-page":"R95","DOI":"10.1186\/ar3370","volume":"13","author":"H Appel","year":"2011","unstructured":"Appel H, Maier R, Wu P, Scheer R, Hempfing A, Kayser R, Thiel A, Radbruch A, Loddenkemper C, Sieper J (2011) Analysis of IL-17(+) cells in facet joints of patients with spondyloarthritis suggests that the innate immune pathway might be of greater relevance than the Th17-mediated adaptive immune response. Arthritis Res Ther 13(3):R95\u2013R95","journal-title":"Arthritis Res Ther"},{"issue":"4","key":"5207_CR43","doi-asserted-by":"crossref","first-page":"259","DOI":"10.3109\/08916934.2014.976630","volume":"48","author":"S Ebihara","year":"2015","unstructured":"Ebihara S, Date F, Dong Y, Ono M (2015) Interleukin-17 is a critical target for the treatment of ankylosing enthesitis and psoriasis-like dermatitis in mice. Autoimmunity 48(4):259\u2013266","journal-title":"Autoimmunity"},{"issue":"6","key":"5207_CR44","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1007\/s10067-015-2961-7","volume":"34","author":"SK Raychaudhuri","year":"2015","unstructured":"Raychaudhuri SK, Saxena A, Raychaudhuri SP (2015) Role of IL-17 in the pathogenesis of psoriatic arthritis and axial spondyloarthritis. Clin Rheumatol 34(6):1019\u20131023","journal-title":"Clin Rheumatol"},{"issue":"11","key":"5207_CR45","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1038\/s41584-018-0091-8","volume":"14","author":"EM Gravallese","year":"2018","unstructured":"Gravallese EM, Schett G (2018) Effects of the IL-23-IL-17 pathway on bone in spondyloarthritis. Nat Rev Rheumatol 14(11):631\u2013640","journal-title":"Nat Rev Rheumatol"},{"issue":"9906","key":"5207_CR46","doi-asserted-by":"crossref","first-page":"1705","DOI":"10.1016\/S0140-6736(13)61134-4","volume":"382","author":"D Baeten","year":"2013","unstructured":"Baeten D, Baraliakos X, Braun J, Sieper J, Emery P, van der Heijde D, McInnes I, van Laar JM, Landew\u00e9 R, Wordsworth P, Wollenhaupt J, Kellner H, Paramarta J, Wei J, Brachat A, Bek S, Laurent D, Li Y, Wang YA, Bertolino AP, Gsteiger S, Wright AM, Hueber W (2013) Anti-interleukin-17A monoclonal antibody secukinumab in treatment of ankylosing spondylitis: a randomised, double-blind, placebo-controlled trial. Lancet 382(9906):1705\u20131713","journal-title":"Lancet"},{"issue":"10","key":"5207_CR47","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1038\/nri1200","volume":"3","author":"T Calandra","year":"2003","unstructured":"Calandra T, Roger T (2003) Macrophage migration inhibitory factor: a regulator of innate immunity. Nat Rev Immunol 3(10):791\u2013800","journal-title":"Nat Rev Immunol"},{"issue":"1","key":"5207_CR48","doi-asserted-by":"crossref","first-page":"34","DOI":"10.3109\/s10165-009-0230-9","volume":"20","author":"LD Kozaci","year":"2010","unstructured":"Kozaci LD, Sari I, Alacacioglu A et al (2010) Evaluation of inflammation and oxidative stress in ankylosing spondylitis: a role for macrophage migration inhibitory factor. Mod Rheumatol 20(1):34\u201339","journal-title":"Mod Rheumatol"},{"issue":"6","key":"5207_CR49","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1136\/annrheumdis-2012-202208","volume":"73","author":"NT Baerlecken","year":"2014","unstructured":"Baerlecken NT, Nothdorft S, Stummvoll GH, Sieper J, Rudwaleit M, Reuter S, Matthias T, Schmidt RE, Witte T (2014) Autoantibodies against CD74 in spondyloarthritis. Ann Rheum Dis 73(6):1211\u20131214","journal-title":"Ann Rheum Dis"},{"issue":"5","key":"5207_CR50","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1002\/art.40777","volume":"71","author":"E Riechers","year":"2019","unstructured":"Riechers E, Baerlecken N, Baraliakos X et al (2019) Sensitivity and specificity of autoantibodies against CD74 in nonradiographic axial Spondyloarthritis. Arthritis Rheum 71(5):729\u2013735","journal-title":"Arthritis Rheum"},{"issue":"6","key":"5207_CR51","doi-asserted-by":"crossref","first-page":"1369","DOI":"10.1007\/s10067-017-3668-8","volume":"36","author":"X Wang","year":"2017","unstructured":"Wang X, Ma C, Li P et al (2017) Effects of iguratimod on the levels of circulating regulators of bone remodeling and bone remodeling markers in patients with rheumatoid arthritis. Clin Rheumatol 36(6):1369\u20131377","journal-title":"Clin Rheumatol"},{"issue":"12","key":"5207_CR52","doi-asserted-by":"crossref","first-page":"44","DOI":"10.14715\/cmb\/2016.62.13.8","volume":"62","author":"XT Wang","year":"2016","unstructured":"Wang XT, Li P, Xu TS et al (2016) Effect of iguratimod and methotrexate on RANKL and OPG expression in serum and IL-1\u03b2-induced fibroblast-like synoviocytes from patients with rheumatoid arthritis. Cell Mol Biol 62(12):44\u201350","journal-title":"Cell Mol Biol"},{"issue":"26","key":"5207_CR53","doi-asserted-by":"crossref","first-page":"2563","DOI":"10.1056\/NEJMra1406182","volume":"374","author":"JD Taurog","year":"2016","unstructured":"Taurog JD, Chhabra A, Colbert RA (2016) Ankylosing spondylitis and axial spondyloarthritis. N Engl J Med 374(26):2563\u20132574","journal-title":"N Engl J Med"},{"issue":"4","key":"5207_CR54","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1177\/1759720X12441276","volume":"4","author":"PN Sambrook","year":"2012","unstructured":"Sambrook PN, Geusens P (2012) The epidemiology of osteoporosis and fractures in ankylosing spondylitis. Ther Adv Musculoskelet Dis 4(4):287\u2013292","journal-title":"Ther Adv Musculoskelet Dis"},{"issue":"4","key":"5207_CR55","first-page":"620","volume":"27","author":"CH Im","year":"2009","unstructured":"Im CH, Kang EH, Ki JY, Shin DW, Choi HJ, Chang EJ, Lee EY, Lee YJ, Lee EB, Kim HH, Song YW (2009) Receptor activator of nuclear factor kappa B ligand-mediated osteoclastogenesis is elevated in ankylosing spondylitis. Clin Exp Rheumatol 27(4):620\u2013625","journal-title":"Clin Exp Rheumatol"},{"issue":"12","key":"5207_CR56","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1038\/s41584-019-0294-7","volume":"15","author":"J Sieper","year":"2019","unstructured":"Sieper J, Poddubnyy D, Miossec P (2019) The IL-23-IL-17 pathway as a therapeutic target in axial spondyloarthritis. Nat Rev Rheumatol 15(12):747\u2013757","journal-title":"Nat Rev Rheumatol"},{"issue":"4","key":"5207_CR57","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1097\/BOR.0000000000000404","volume":"29","author":"B Neerinckx","year":"2017","unstructured":"Neerinckx B, Lories R (2017) Mechanisms, impact and prevention of pathological bone regeneration in spondyloarthritis. Curr Opin Rheumatol 29(4):287\u2013292","journal-title":"Curr Opin Rheumatol"},{"key":"5207_CR58","doi-asserted-by":"crossref","first-page":"2668","DOI":"10.3389\/fimmu.2018.02668","volume":"9","author":"A Watad","year":"2018","unstructured":"Watad A, Bridgewood C, Russell T et al (2018) The early phases of ankylosing spondylitis: emerging insights from clinical and basic science. Front Immunol 9:2668","journal-title":"Front Immunol"},{"issue":"6","key":"5207_CR59","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1080\/03009742.2017.1390150","volume":"47","author":"Y Luo","year":"2018","unstructured":"Luo Y, Zheng N, Wu R (2018) Is iguratimod effective in refractory axial spondyloarthritis? Scand J Rheumatol 47(6):518\u2013520","journal-title":"Scand J Rheumatol"},{"issue":"3","key":"5207_CR60","first-page":"235","volume":"26","author":"YY Qiu","year":"2016","unstructured":"Qiu YY, Tang Y, Rui JB, Li J (2016) Clinical observation on treatment of refractory ankylosing spondylitis by Iguratimod. J Jiangsu Univ (Medicine Edition) 26(3):235\u2013239","journal-title":"J Jiangsu Univ (Medicine Edition)"},{"issue":"13","key":"5207_CR61","first-page":"92","volume":"34","author":"BJ Huang","year":"2018","unstructured":"Huang BJ, Ma JX (2018) Observation of short-term efficacy of iguratimod in the treatment of ankylosing spondylitis. Chin Commun Doctors 34(13):92\u201393","journal-title":"Chin Commun Doctors"},{"issue":"14","key":"5207_CR62","first-page":"9","volume":"12","author":"YP Lin","year":"2019","unstructured":"Lin YP, Liu H, Gao JT (2019) Initial clinical observation on treatment of ankylosing spondylitis by Iguratimod. J Clin Rational Drug Use 12(14):9\u201313","journal-title":"J Clin Rational Drug Use"},{"issue":"12","key":"5207_CR63","first-page":"915","volume":"50","author":"BJ Xu","year":"2019","unstructured":"Xu BJ, Mo XQ, Xue XQ, Wu Y (2019) Study of the efficacy and safety of iguratimod in the treatment of ankylosing spondylitis. J New Med 50(12):915\u2013918","journal-title":"J New Med"},{"issue":"1","key":"5207_CR64","first-page":"118","volume":"27","author":"HQ Zeng","year":"2016","unstructured":"Zeng HQ, Kong WH, Zhuang P, Dong HJ, Yi ZH, Chen XP, Fu CZ, Ye ZH (2016) Observation of efficacy of iguratimod in the treatment of ankylosing spondylitis. Hainan Med J 27(1):118\u2013120","journal-title":"Hainan Med J"}],"container-title":["Clinical Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-020-05207-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10067-020-05207-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-020-05207-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,7]],"date-time":"2024-08-07T01:59:45Z","timestamp":1722995985000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10067-020-05207-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,6,6]]},"references-count":64,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,1]]}},"alternative-id":["5207"],"URL":"https:\/\/doi.org\/10.1007\/s10067-020-05207-z","relation":{},"ISSN":["0770-3198","1434-9949"],"issn-type":[{"value":"0770-3198","type":"print"},{"value":"1434-9949","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,6,6]]},"assertion":[{"value":"30 April 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 May 2020","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 May 2020","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 June 2020","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"None.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclosures"}}]}}